Basit öğe kaydını göster

dc.contributor.authorSinghal, Aneesh B.
dc.contributor.authorHajj-Ali, Rula A.
dc.contributor.authorTopcuoglu, Mehmet A.
dc.contributor.authorFok, Joshua
dc.contributor.authorBena, James
dc.contributor.authorYang, Donsheng
dc.contributor.authorCalabrese, Leonard H.
dc.date.accessioned2019-12-10T11:25:55Z
dc.date.available2019-12-10T11:25:55Z
dc.date.issued2011
dc.identifier.issn0003-9942
dc.identifier.urihttps://doi.org/10.1001/archneurol.2011.68
dc.identifier.urihttp://hdl.handle.net/11655/15732
dc.description.abstractObjectives: To compare the clinical, laboratory, and imaging features of patients with reversible cerebral vasoconstriction syndromes evaluated at 2 academic centers, compare subgroups, and investigate treatment effects. Design: Retrospective analysis. Setting: Massachusetts General Hospital (n = 84) or Cleveland Clinic (n = 55). Patients: One hundred thirty-nine patients with reversible cerebral vasoconstriction syndromes. Main Outcome Measures: Clinical, laboratory, and imaging features; treatment; and outcomes. Results: The mean age was 42.5 years, and 81% were women. Onset with thunderclap headache was documented in 85% and 43% developed neurological deficits. Prior migraine was documented in 40%, vasoconstrictive drug exposure in 42%, and recent pregnancy in 9%. Admission computed tomography or magnetic resonance imaging was normal in 55%; however, 81% ultimately developed brain lesions including infarcts (39%), convexity subarachnoid hemorrhage (34%), lobar hemorrhage (20%), and brain edema (38%). Cerebral angiographic abnormalities typically normalized within 2 months. Nearly 90% had good clinical outcome; 9% developed severe deficits; and 2% died. In the combined cohort, calcium channel blocker therapy and symptomatic therapy alone showed no significant effect on outcome; however, glucocorticoid therapy showed a trend for poor outcome (P = .08). Subgroup comparisons based on prior headache status and identified triggers (vasoconstrictive drugs, pregnancy, other) showed no major differences. Conclusion: Patients with reversible cerebral vasoconstriction syndromes have a unique set of clinical imaging features, with no significant differences between subgroups. Prospective studies are warranted to determine the effects of empirical treatment with calcium channel blockers and glucocorticoids.
dc.language.isoen
dc.publisherAmer Medical Assoc
dc.relation.isversionof10.1001/archneurol.2011.68
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeurosciences & Neurology
dc.titleReversible Cerebral Vasoconstriction Syndromes Analysis of 139 Cases
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalArchives Of Neurology
dc.contributor.departmentNöroloji
dc.identifier.volume68
dc.identifier.issue8
dc.identifier.startpage1005
dc.identifier.endpage1012
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster